Journal List > J Korean Soc Transplant > v.25(2) > 1034337

J Korean Soc Transplant. 2011 Jun;25(2):116-122. Korean.
Published online June 30, 2011.  https://doi.org/10.4285/jkstn.2011.25.2.116
Copyright © 2011 The Korean Society for Transplantation
A Case of Late Mixed Acute Humoral and Cellular Rejection Successfully Treated with Rituximab, Plasmapheresis and IVIg
Seong Min Kim, M.D.,1 Joon Seok Oh, M.D.,1 Jee Min Jun, M.D.,1 Yong Kee Park, M.D.,1 Yong Hun Sin, M.D.,1 Joong Kyung Kim, M.D.,1 Kill Huh, M.D.,2 and Yong Jin Kim, M.D.3
1Department of Internal Medicine, Bong Seng Memorial Hospital, Busan, Korea.
2Department of General Surgery, Bong Seng Memorial Hospital, Busan, Korea.
3Department of Pathology, Yeungnam University College of Medicine, Daegu, Korea.

Corresponding author (Email: syhpmj@hanmail.net )
Received April 16, 2011; Revised May 26, 2011; Accepted May 31, 2011.

Abstract

Acute antibody-mediated rejection (AMR) developing simultaneously with acute cellular rejection has been rarely reported as a long-term complication of renal transplantation, and it can present on top of another chronic pathology affecting the graft. A 51-year-old female patient with chronic kidney disease of unknown etiology received renal transplantation 12 years ago from a living unrelated donor with 3 HLA mismatches. She received induction therapy with methylprednisolone and was maintained on steroids, mycophenolate mofetil and cyclosporine A (CsA). For a period of twelve years post-transplantation, she was clinically and biochemically stable. She presented with a rise in serum creatinine (SCr.) from 1.3 mg/dL to 2.4 mg/dL but did not have proteinuria. Graft biopsy revealed findings suggestive of acute cellular rejection on top of antibody-mediated rejection (type II) and chronic calcineurin inhibitor toxicity. Panel reactive antibody (PRA) test levels were 3.6%, 91.7% for class I and II respectively. The patient was treated with high-dose methylprednisolone for 3 days but serum creatinine was not fully normalised. After 2 weeks from initial methyl-PDS pulse therapy, she received intravenous immunoglobulin, plasma exchange and anti-CD20 (rituximab). Cyclosporine was changed to tacrolimus. She achieved a complete response, and SCr. was maintained at 1.3 mg/dL without proteinuria. Follow-up PRA test levels were 0%, 75% for class I and II. Current therapies have had considerable success in reversing mixed, acute humoral and cellular rejection since it is being identified quickly and treated aggressively. The best use of rituximab to treat AMR should be evaluated in controlled trials using dosing strategies that include longer courses or retreatment schedules.

Keywords: Transplantation; Graft rejection; Rituximab; Plasmapheresis

Figures


Fig. 1
Clinical course; MPDS pulse, 250 mg iv bid for 3days; plasmapheresis, 1 plasma volume, 5% albumin replacement solution, COBE® Spectra Apheresis System; Rituximab 200 mg/body single infusion. Abbreviations: CsA, cyclosporine; MMF, mycophenolate mofetil; PDS, prednisone; Bx., biopsy; MPDS, methyl prednisolone; PP/IVIG, plasmapheresis with intravenous immune globulin.
Click for larger image


Fig. 2
Light microscopically, there was mild to moderate intimal arteritis (PAS stain, original magnification ×400)
Click for larger image


Fig. 3
Light microscopically, lymphocytes infiltration underneath the endothelium of large vessels is noted (PAS stain, original magnification ×400).
Click for larger image


Fig. 4
Immunofluorescent microscopically, there was diffuse staining for C4d in the peritubular capillaries(original magnification ×200).
Click for larger image

References
1. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003;3:665–673.
2. Feucht HE. Complement C4d in graft capillaries -- the missing link in the recognition of humoral alloreactivity. Am J Transplant 2003;3:646–652.
3. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003;3:708–714.
4. Halloran PF. The clinical importance of alloantibody-mediated rejection. Am J Transplant 2003;3:639–640.
5. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004;4:1289–1295.
6. Colvin RB. Chronic allograft nephropathy. N Engl J Med 2003;349:2288–2290.
7. Gautreau C, Suberbielle C, Andrade J, Charron D. Donor-specific antibody detection for diagnosis of antibody-mediated rejection in kidney transplantation. Clin Transpl 2006:502.
8. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007;18:1046–1056.
9. Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002;13:242–251.
10. Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: is C4d a magic marker? Nephrol Dial Transplant 2003;18:2232–2239.
11. Yang CW, Oh EJ, Lee SB, Moon IS, Kim DG, Choi BS, et al. Detection of donor-specific anti-HLA class I and II antibodies using antibody monitoring system. Transplant Proc 2006;38:2803–2806.
12. Herzenberg AM, Gill JS, Djurdjev O, Magil AB. C4d deposition in acute rejection: an independent long-term prognostic factor. J Am Soc Nephrol 2002;13:234–241.
13. Gibney EM, Cagle LR, Freed B, Warnell SE, Chan L, Wiseman AC. Detection of donor-specific antibodies using HLA-coated microspheres:another tool for kidney transplant risk stratification. Nephrol Dial Transplant 2006;21:2625–2629.
14. Weinstein D, Braun WE, Cook D, McMahon JT, Myles J, Protiva D. Ultra-late antibody-mediated rejection 30 years after a living-related renal allograft. Am J transplant 2005;5:2576–2578.
15. Poduval RD, Kadambi PV, Josephson MA, Cohn RA, Harland RC, Javaid B, et al. Implications of immunohistochemical detection of C4d along peritubular capillaries in late acute renal allograft rejection. Transplantation 2005;79:228–235.
16. Kedainis RL, Koch MJ, Brennan DC, Liapis H. Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant 2009;9:812–819.
17. Chung BH, Jung HS, Jeon SH, Park YJ, Choi SO, Yoon JM, et al. Clinical significance of C4d-positivity in renal transplant recipients with acute rejection. J Korean Soc Transplant 2005;19:137–141.
18. Watschinger B, Pascual M. Capillary C4d deposition as a marker of humoral immunity in renal allograft rejection. J Am Soc Nephrol 2002;13:2420–2423.
19. Pascual M, Saidman S, Tolkoff-Rubin N, Williams WW, Mauiyyedi S, Duan JM, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998;66:1460–1464.
20. Crespo M, Lozano M, Sole M, Mila J, Esforzado N, Martorell J, et al. Diagnosis and treatment of acute humoral rejection after kidney transplantation: preliminary experience. Transplant Proc 2003;35:1677–1678.
21. Ibernon M, Gil-Vernet S, Carrera M, Serón D, Moreso F, Bestard O, et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant Proc 2005;37:3743–3745.
22. Jordan SC, Vo AA, Toyoda M, Tyan D, Nast CC. Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection. Pediatr Transplant 2005;9:155–161.
23. Casadei DH, Rial MC, Raimondi E, Goldberg J, Argento J, Haas E. Complementary data about the inhibitory effects of intravenous immunoglobulins in vitro and in vivo. Transplantation 1997;63:1191–1192.
24. Kubori T, Mezaki T, Kaji R, Kimura J, Hamaguchi K, Hirayama K, et al. The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. No to Shinkei 1999;51:127–135.
25. Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 2002;9:565–572.
26. Becker YT, Samaniego-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl Int 2006;19:621–628.
27. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6:859–866.
28. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242–251.
29. Faguer S, Kamar N, Guilbeaud-Frugier C, Fort M, Modesto A, Mari A, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007;83:1277–1280.
30. Shirakawa H, Ishida H, Shimizu T, Omoto K, Iida S, Toki D, et al. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. Clin Transplant. 2010 Dec 22;
[Epub ahead of print].
31. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004;103:4424–4428.
32. Lee S, Joo SH, Kim JS, Goldstein MJ, Cohen DJ, Hardy MA. Rituximab rescue for refractory antibody mediated rejection after kidney transplantation. J Korean Soc Transplant 2004;18:140–143.
33. Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol 2003;25:119–140.
34. Wong W, Lee RA, Saidman SL, Smith RN, Zorn E. Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports. Clin Transpl 2009:401–405.
TOOLS
Similar articles

Combination Treatment of Rituximab and Plasmapheresis in Acute Cellular Rejection with Focal Segmental Glomerular Sclerosis after Renal Transplantation

Successful Renal Transplantation with Desensitization in Highly Sensitized Patients: A Single Center Experience

Current Issues in the Treatment of Chronic Antibody-Mediated Rejection in Kidney Transplantation

Long-term outcomes of emergency ABO-incompatible living donor liver transplantation using a modified desensitization protocol for highly sensitized patients with acute liver failure: A case report

An Experience of ABO-incompatible Kidney Transplantation Using Plasmapheresis and Anti-CD20 Monoclonal Antibody